Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02444286

The RESHAPE-HF1-FU Study

Observational Study of Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation - Follow Up of the Former Participants in the RESHAPE-HF Trial (Abbott Vascular).

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To evaluate the safety and efficiency of the MitraClip system in the treatment of patients with clinically significant mitral regurgitation with New York Heart Association (NYHA) Functional Class II to IV chronic heart failure.

Detailed description

The purpose of the RESHAPE-HF1-FU Study is to follow up the safety and effectiveness of the MitraClip System in the treatment of clinically significant Functional Mitral Regurgitation (FMR) in patients with New York Heart Association (NYHA) Functional Class III or IV chronic heart failure, former participants in the RESHAPE-HF Trial (Abbott Vascular).

Conditions

Timeline

Start date
2017-01-01
Primary completion
2018-01-01
Completion
2018-01-01
First posted
2015-05-14
Last updated
2024-01-05

Locations

2 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT02444286. Inclusion in this directory is not an endorsement.

The RESHAPE-HF1-FU Study (NCT02444286) · Clinical Trials Directory